Efficacy and Safety of Atacicept in IgA Nephropathy
Status:
Terminated
Trial end date:
2020-02-07
Target enrollment:
Participant gender:
Summary
This main purpose of this study was to evaluate the safety, tolerability, dose response and
efficacy of Atacicept in participants with IgA nephropathy and persistent proteinuria. The
study hypothesis was that treatment with Atacicept would reduce proteinuria compared to
placebo.